TTR and cardiac amyloidosis: Although important developments in the field of ATTR-CM were achieved, there are still important unanswered questions: (1) the optimal imaging and biomarker protocols for screening of asymptomatic variant TTR carriers; (2) the understanding of unclear diagnostic features in cardiac amyloidosis (CA), and (3) the best markers (imaging and/or biological) for monitoring response to therapy in ATTR-CM [9].